GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (OTCPK:MBXBF) » Definitions » YoY Rev. per Sh. Growth

Microbix Biosystems (Microbix Biosystems) YoY Rev. per Sh. Growth : 253.85% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Microbix Biosystems YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Microbix Biosystems's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was 253.85%.

Microbix Biosystems's Revenue per Share for the three months ended in Dec. 2023 was $0.05.


Microbix Biosystems YoY Rev. per Sh. Growth Historical Data

The historical data trend for Microbix Biosystems's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems YoY Rev. per Sh. Growth Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 -26.92 36.84 -2.88 -12.87

Microbix Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.85 -22.22 11.11 - 253.85

Microbix Biosystems YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Microbix Biosystems's YoY Rev. per Sh. Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Sep. 2023 )
=(Revenue per Share (A: Sep. 2023 )-Revenue per Share (A: Sep. 2022 ))/ | Revenue per Share (A: Sep. 2022 ) |
=(0.088-0.101)/ | 0.101 |
=-12.87 %

Microbix Biosystems's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(0.046-0.013)/ | 0.013 |
=253.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (Microbix Biosystems) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

Microbix Biosystems (Microbix Biosystems) Headlines

From GuruFocus

Microbix Attains Health Canada Establishment Licensing

By GlobeNewswire GlobeNewswire 04-21-2020

Microbix Announces Extension of Warrant Expiry Date

By GlobeNewswire GlobeNewswire 05-18-2023

Microbix Announces Annual and Special Meeting Voting Results

By GlobeNewswire GlobeNewswire 04-01-2020